← Leaderboards
Pankaj Kumar Singh
Pennsylvania State Univ Hershey Med Ctr
$18,899,559
Attributed
$20,165,684
Total exposure
13
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,462,262 · 14
By mechanism
R01$14,388,239 · 5
U54$7,811,081 · 7
P50$1,696,749 · 1
P01$1,566,193 · 1
Top collaborators
- Shengyu Yang4 shared
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasNeoplastic CellMetabolicSignal TransductionResponseMediatingPancreatic NeoplasmCellsTumorChemotherapyResistanceMetabolomicsInsightTumor ProgressionMetabolismNeoplasm MetastasisMolecularGenesMalignant NeoplasmsStromal NeoplasmDiagnosisClinical TreatmentTumor GrowthPancreatic Ductal Adenocarcinoma
Grant awards (71)
Pancreatic Cancer ARTNet Center$1,381,764
U54 · FY2025 · CA · contact PI
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression$640,552
R01 · FY2025 · CA
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer$430,604
R01 · FY2025 · CA · contact PI
Administrative Core$275,946
U54 · FY2025 · CA · contact PI
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer$221,403
U54 · FY2025 · CA · contact PI
Cancer Metabolism Core$84,204
U54 · FY2025 · CA · contact PI
Pancreatic Cancer ARTNet Center$1,202,713
U54 · FY2024 · CA · contact PI
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression$608,525
R01 · FY2024 · CA
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer$409,073
R01 · FY2024 · CA · contact PI
Administrative Core$291,865
U54 · FY2024 · CA · contact PI
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer$234,172
U54 · FY2024 · CA · contact PI
Cancer and stromal metabolic reprogramming drives chemotherapy resistance in human models of pancreatic cancer$161,750
U54 · FY2024 · CA · contact PI
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer$161,750
U54 · FY2024 · CA · contact PI
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer$111,354
R01 · FY2024 · CA · contact PI
Cancer Metabolism Core$89,060
U54 · FY2024 · CA · contact PI
Pancreatic Cancer ARTNet Center$1,266,017
U54 · FY2023 · CA · contact PI
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression$627,740
R01 · FY2023 · CA
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer$440,875
R01 · FY2023 · CA · contact PI
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer$421,992
R01 · FY2023 · CA · contact PI
Administrative Core$307,227
U54 · FY2023 · CA · contact PI
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer$246,500
U54 · FY2023 · CA · contact PI
Cancer Metabolism Core$93,747
U54 · FY2023 · CA · contact PI
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer$54,784
R01 · FY2023 · CA · contact PI
Pancreatic Cancer ARTNet Center$1,284,334
U54 · FY2022 · CA · contact PI
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression$655,433
R01 · FY2022 · CA
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer$440,874
R01 · FY2022 · CA · contact PI
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer$430,604
R01 · FY2022 · CA · contact PI
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC Metastasis$310,109
P01 · FY2022 · CA · contact PI
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer$293,941
U54 · FY2022 · CA · contact PI
Administrative Core$118,290
U54 · FY2022 · CA · contact PI
Cancer Metabolism Core$96,398
U54 · FY2022 · CA · contact PI
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer$54,784
R01 · FY2022 · CA · contact PI
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer$477,871
R01 · FY2021 · CA · contact PI
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer$473,142
R01 · FY2021 · CA · contact PI
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer$434,065
R01 · FY2021 · CA · contact PI
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC Metastasis$316,437
P01 · FY2021 · CA · contact PI
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer$57,112
R01 · FY2021 · CA · contact PI
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer$20,000
R01 · FY2021 · CA · contact PI
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer$857
R01 · FY2021 · CA · contact PI
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer$565,549
R01 · FY2020 · CA · contact PI
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer$473,142
R01 · FY2020 · CA · contact PI
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer$454,065
R01 · FY2020 · CA · contact PI
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC Metastasis$316,437
P01 · FY2020 · CA · contact PI
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer$588,368
R01 · FY2019 · CA · contact PI
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer$473,142
R01 · FY2019 · CA · contact PI
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer$464,368
R01 · FY2019 · CA · contact PI
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC Metastasis$306,945
P01 · FY2019 · CA · contact PI
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer$84,217
R01 · FY2019 · CA · contact PI
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer$478,728
R01 · FY2018 · CA · contact PI
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer$454,065
R01 · FY2018 · CA · contact PI
Targeting Metabolic Alterations to Improve Survival in Pancreatic Cancer$367,220
P50 · FY2018 · CA · contact PI
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC Metastasis$316,265
P01 · FY2018 · CA · contact PI
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer$152,500
R01 · FY2018 · CA · contact PI
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer$54,458
R01 · FY2018 · CA · contact PI
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer$478,728
R01 · FY2017 · CA · contact PI
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer$454,065
R01 · FY2017 · CA · contact PI
Targeting Metabolic Alterations to Improve Survival in Pancreatic Cancer$379,895
P50 · FY2017 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$437,718
R01 · FY2016 · CA · contact PI
Targeting Metabolic Alterations to Improve Survival in Pancreatic Cancer$324,405
P50 · FY2016 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$86,074
R01 · FY2016 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$60,494
R01 · FY2016 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$372,693
R01 · FY2015 · CA · contact PI
Targeting Metabolic Alterations to Improve Survival in Pancreatic Cancer$300,825
P50 · FY2015 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$81,651
R01 · FY2015 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$60,494
R01 · FY2015 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$22,890
R01 · FY2015 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$403,980
R01 · FY2014 · CA · contact PI
Targeting Metabolic Alterations to Improve Survival in Pancreatic Cancer$324,404
P50 · FY2014 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$81,651
R01 · FY2014 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$386,339
R01 · FY2013 · CA · contact PI
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer$428,619
R01 · FY2012 · CA · contact PI